<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945733</url>
  </required_header>
  <id_info>
    <org_study_id>CR109026</org_study_id>
    <secondary_id>61186372GIC2001</secondary_id>
    <nct_id>NCT04945733</nct_id>
  </id_info>
  <brief_title>A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer</brief_title>
  <official_title>A Phase 2, Open-label Study of Amivantamab in Subjects With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the activity of amivantamab in gastric cancer&#xD;
      (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary&#xD;
      antitumor activity of amivantamab in selected GC and EC population (Phase 2b).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>ORR is defined as the percentage of participants who achieve either complete response (CR) or partial response (PR), determined by investigator assessment using response evaluation criteria in solid tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>DCR is defined as the percentage of participants achieving complete or partial response or stable disease for at least 6 weeks as defined by RECIST Version1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>PFS is defined as the time from first dose until the date of objective disease progression or death (by any cause in the absence of progression), whichever comes first, based on investigator assessment using RECIST Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: Overall Survival (OS)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>OS is defined as the time from the date of first dose until the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Amivantamab</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>Cmax is defined as maximum concentration of amivantamab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) of Amivantamab</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>Tmax is defined as time to reach maximum serum concentration of amivantamab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From t1 to t2 Time (AUC[t1-t2]) of Amivantamab</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>AUC(t1-t2) is defined as the area under the serum concentration-time curve from time t1 to t2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to End of Dosing Interval (AUCtau)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>AUCtau is the measure of the serum drug concentration from time zero to end of dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>Ctrough is defined as the serum concentration of amivantamab immediately prior to the next drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (RA) of Amivantamab</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>RA is calculated as area under the plasma concentration-time curve from time zero to 24 hours (AUC [0-24]) value at steady state divided by AUC (0-24) value after first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Amivantamab Antibodies</measure>
    <time_frame>Up to 1 year and 10 months</time_frame>
    <description>Serum samples will be collected to detect the anti-drug antibodies to amivantamab. The detection and characterization of antibodies to amivantamab will be performed using a validated immunoassay method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Amivantamab: Gastric Cancer (GC) Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Phase 2a GC cohorts will receive intravenous (IV) infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight less than (&lt;) 80 kilograms (kg) will receive IV infusion of amivantamab 1,050 milligrams (mg) and participants with body weight greater than or equal to (&gt;=) 80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). Phase 2b GC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amivantamab: Esophageal Cancer (EC) Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Phase 2a EC cohorts will receive IV infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight &lt;80 kg will receive IV infusion of amivantamab 1,050 mg and participants with body weight &gt;=80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). Phase 2b EC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amivantamab</intervention_name>
    <description>Amivantamab will be administered intravenously.</description>
    <arm_group_label>Amivantamab: Esophageal Cancer (EC) Cohorts</arm_group_label>
    <arm_group_label>Amivantamab: Gastric Cancer (GC) Cohorts</arm_group_label>
    <other_name>JNJ-61186372</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have histologically or cytologically confirmed gastric (including&#xD;
             gastroesophageal junction [GEJ]) or esophageal cancer (EC) that is locally advanced,&#xD;
             unresectable, or metastatic, and not eligible for curative treatment&#xD;
&#xD;
          -  Participant must have measurable disease according to Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) Version 1.1. If only 1 measurable lesion exists, it may be used&#xD;
             for the screening biopsy if the baseline tumor assessment scans are performed greater&#xD;
             than or equal to (&gt;=) 7 days after the biopsy&#xD;
&#xD;
          -  Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0&#xD;
             or 1&#xD;
&#xD;
        Gastric or GEJ Cancer Only - Must be refractory or ineligible to at least 2 prior lines of&#xD;
        standard of care systemic therapy. Prior therapies must include fluoropyrimidine- and&#xD;
        platinum-based chemotherapy. Participants with known human epidermal growth factor receptor&#xD;
        (HER) 2 expression must have had HER2 targeting therapy as part of the prior therapy&#xD;
&#xD;
        Esophageal Cancer Only&#xD;
&#xD;
        - Must be refractory or intolerant to at least 1 prior line of systemic therapy. Prior&#xD;
        therapies must include fluoropyrimidine-, and platinum-based chemotherapy (including&#xD;
        chemoradiation therapy given as stage intravenous [IV] setting)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has an uncontrolled illness, including but not limited to the following:&#xD;
             diabetes; ongoing or active bacterial infection (includes infection requiring&#xD;
             treatment with antimicrobial therapy [participants will be required to complete&#xD;
             antibiotics 1 week before enrollment]), symptomatic viral infection, or any other&#xD;
             clinically significant infection; active bleeding diathesis and psychiatric&#xD;
             illness/social situation that would limit compliance with study requirements&#xD;
&#xD;
          -  Participant has received prior epidermal growth factor receptor (EGFR) or&#xD;
             tyrosine-protein kinase mesenchymal-epithelial transition (cMet)-directed therapies&#xD;
&#xD;
          -  Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or&#xD;
             treatment with an investigational anticancer agent within 2 weeks or 4 half-lives&#xD;
             whichever is longer or had radiation therapy within 4 weeks before the first&#xD;
             administration of study treatment. For agents with long half-lives, the maximum&#xD;
             required time since last dose is 28 days. Toxicities from previous anticancer&#xD;
             therapies should have resolved to baseline levels or to Grade 1 or less, (except for&#xD;
             alopecia or post-radiation skin changes [any grade], Grade less than or equal to [&lt;=]&#xD;
             2 peripheral neuropathy, and Grade &lt;=2 hypothyroidism stable on hormone replacement)&#xD;
&#xD;
          -  Participant has untreated brain metastases (a participant with definitively, locally&#xD;
             treated metastases who is clinically stable, asymptomatic, and off corticosteroid&#xD;
             treatment for at least 2 weeks prior to the first administration of study treatment is&#xD;
             eligible), history of leptomeningeal disease or spinal cord compression that has not&#xD;
             been treated definitively with surgery or radiation. If brain metastases are diagnosed&#xD;
             on screening imaging, the participant may be rescreened for eligibility after&#xD;
             definitive treatment&#xD;
&#xD;
          -  Participant has a history of (non-infectious) interstitial lung disease&#xD;
             (ILD)/pneumonitis that required steroids, or has current ILD/pneumonitis, or where&#xD;
             suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Esophageal&#xD;
             cancer participants with history of completely resolved radiation pneumonitis (defined&#xD;
             as radiographically stable for 3 months prior to enrollment without need of any&#xD;
             treatment) may be enrolled&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer center</name>
      <address>
        <city>Kitaadachi-gun</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya-Shi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109026</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amivantamab-vmjw</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

